Post-COVID-19 Hair Disorders in the City of Iguatu-PR




Hair loss; Coronavirus; Telogen effluvium; Alopecia areata.


Objective: To identify the prevalence of hair disorders after COVID-19 infection in individuals from the city of Iguatu-PR. Methodology: quantitative and qualitative exploratory-descriptive research, carried out through the application of an online questionnaire to patients who attended the basic health unit of the municipality during the month of August 2022, being selected only those patients aged between 18 and 60 years that presented the infection by the new coronavirus. Results: 58.75% of respondents reported having some sequel after infection by COVID-19, in relation to hair loss, 53.75% of individuals reported the development of hair loss after infection. 55.8% of the subjects reported thinning of the hair strands, and 86% of the subjects reported that the hair loss was diffuse. As for the time elapsed until the onset of the fall, the time range varied between 1 week and 6 months or more after the infection for the first signs of fall to appear, 30.23% of people reported that the symptoms appeared 1 month after the infection. The duration of hair loss did not exceed 6 months in 81.58% of respondents, only 18.42% of the 43 patients reported that the hair loss lasted for more than 6 months. Conclusion: COVID-19 can lead to the development of hair disorders, among them, telogen effluvium is more prevalent. More information should be sought to actually clarify the relationship between COVID-19 and hair loss, studies with larger populations bring more representative results.


Aksoy, H., Yıldırım, U. M., Ergen, P., & Gürel, M. S. (2021). COVID ‐19 induced telogen effluvium. Dermatologic Therapy.

Aryanian, Z., Balighi, K., Hatami, P., Afshar, Z. M., & Mohandesi, N. A. (2022). The role of SARS-CoV-2 infection and its vaccines in various types of hair loss. Dermatologic Therapy.

Chams, N., Chams, S., Badran, R., Shams, A., Araji, A., Raad, M., Mukhopadhyay, S., Stroberg, E., Duval, E. J., Barton, L. M., & Hajj Hussein, I. (2020). COVID-19: A Multidisciplinary Review. Frontiers in Public Health, 8.

Chien Yin, G. O., Siong-See, J. L., & Wang, E. C. E. (2021). Telogen Effluvium – a review of the science and current obstacles. Journal of Dermatological Science, 101(3), 156–163.

Do Lago, S. J. P. (2022). Relação entre déficit de vitamina D e alopecia: uma revisão bibliográfica.

Gress, J. B., Silveira, A. de O., Monteiro, B. C., Altoé, E. de C. B., Eleutério, F. B., Surdi, K. C., Santiago, M. G. S., Rodrigues, P. L. A., & Assis, L. de. (2022). Eflúvio telógeno pós-infecção por Covid-19: uma revisão narrativa / Telogen effluvium post Covid-19 infection: a narrative review. Brazilian Journal of Health Review, 5(2), 4692–4701.

Kutlu, Ö., & Metin, A. (2020). Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID ‐19 pandemic. Dermatologic Therapy.

Lopez-Leon, S., Wegman-Ostrosky, T., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., & Villapol, S. (2021). More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Scientific Reports, 11(1), 16144.

Marques, M. A., Porto, C. L. L., Milhomens, A. L. de M., Vieira, J. de M., Gomes, C. C. A., Rocha, A. T. C., & Miller, C. da S. (2020). Alopecia em pacientes anticoagulados. Jornal Vascular Brasileiro, 19.

Natário, J. A. A., Oliveira, L. R., Queiroz, C. C. de, Paula, M. V. M., Moreira, C. B. G., Menezes, L. G., Martin, M. F. O., Guareschi, N., Silva, F. M., & Lima, D. G. (2022). A queda capilar pode ser considerada uma das consequências da COVID-19? Research, Society and Development, 11(1), e11911124935–e11911124935.

Nogueira, M. H. A., & Brandão, B. J. F. (2022). Mesoterapia Capilar: revisão e complicações. BWS Journal , 5 , 1–7.

Novaes, V. V., & Gomes, N. A. A. A. (2020). Uso da biotina na prevenção e tratamento da queda capilar: uma revisão da literatura.

Ohyama, M., Matsudo, K., & Fujita, T. (2022). Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management. The Journal of Dermatology.

Olds, H., Liu, J., Luk, K., Lim, H. W., Ozog, D., & Rambhatla, P. V. (2021). Telogen effluvium associated with COVID-19 infection. Dermatologic Therapy, 34(2), e14761.

Pillai, J., & Mysore, V. (2021). Role of low-level light therapy (LLLT) in androgenetic alopecia. Journal of Cutaneous and Aesthetic Surgery, 14(4), 385.

Rossi, A., Magri, F., Sernicola, A., Michelini, S., Caro, G., Muscianese, M., Di Fraia, M., Chello, C., Fortuna, M. C., & Grieco, T. (2021). Telogen Effluvium after SARS-CoV-2 Infection: A Series of Cases and Possible Pathogenetic Mechanisms. Skin Appendage Disorders, 7(5), 377–381.

Seyf, S., Alijanpour, R., Aryanian, Z., Ezoji, K., & Mahmoudi, M. (2022). Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. JOURNAL of MEDICINE and LIFE, 15.

Simakou, T., Butcher, J. P., Reid, S., & Henriquez, F. L. (2019). Alopecia areata: A multifactorial autoimmune condition. Journal of Autoimmunity, 98, 74–85.

Telles, R. (2020). Alopecias não cicatricial e tratamentos.

Zhou, C., Li, X., Wang, C., & Zhang, J. (2021). Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clinical Reviews in Allergy & Immunology, 61(3), 403–423.



How to Cite

PERELLI, F. C. .; STADLER ROSA LUCCA, P. . Post-COVID-19 Hair Disorders in the City of Iguatu-PR. Research, Society and Development, [S. l.], v. 11, n. 15, p. e273111537145, 2022. DOI: 10.33448/rsd-v11i15.37145. Disponível em: Acesso em: 9 feb. 2023.



Health Sciences